Transdermal delivery of buprenorphine from reduced graphene oxide laden hydrogel to treat osteoarthritis. Issue 7 (3rd May 2021)

• Record Type: Journal Article
• Authors: Zhang, Ziqiang; Wang, Xiaogang; Li, Pengshan; Bai, Minghua; Qi, Wenbing
• Is Part Of: Journal of biomaterials science. Volume 32:Issue 7(2021)
• Page Start: 874
• Page End: 885
• Publication Date: 2021-05-03
• Subjects: Buprenorphine -- osteoarthritis -- reduced graphene oxide -- sustained release -- cold tail flick study; Polymers -- Biocompatibility -- Periodicals; Biomedical materials -- Periodicals; 572.33
• DOI: 10.1080/09205063.2021.1877065
• Languages: English
• ISSNs: 0920-5063

Abstract

Abstract: The patients with chronic pain in osteoarthritis often have insufficient pain relief from non-opioids analgesics. Buprenorphine is a promising molecule for symptomatic relief of chronic pain. The marketed parenteral injections and sublingual tablets have short duration of action (half-life = 2.7 h), which is not suitable to manage chronic pain. The purpose of this research was to design buprenorphine-loaded Pluronic F127-reduced graphene oxide transdermal (noninvasive) hydrogel to achieve sustained release of buprenorphine to manage chronic pain in osteoarthritis. Pluronic F127 was used to stabilize the reduced graphene oxide in hydrogel system. The characterization studies including Fourier transform infrared spectroscopy, X-ray diffraction, and Raman spectroscopy confirmed the synthesis of Pluronic F127-reduced graphene oxide from graphite. The transmission electron microscopy image showed flat nanosheets of reduced graphene oxide (rGO). The developed hydrogel showed desirable pH, viscosity, adhesiveness, hardness, and cohesiveness for transdermal application. The ex vivo release study demonstrated the ability of the Pluronic F127-reduced graphene oxide (P-rGO) hydrogel to prolong release up to 14 days, owing to the strong π–π interactions between the graphene oxide (GO) and the buprenorphine. In cold ethanol tail flick model, the GO hydrogel showed sustained analgesic effect in comparison with hydrogel without rGO. Thus, this study demonstrated the potential of using Pluronic F127-reduced graphene oxide nanocarriers to prolong local analgesia for effective management for chronic pain.